Terms: = Prostate cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
261 results:
1. Ductal Adenocarcinoma of the prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing.
Zara Rozalen A; Martin JM; Rajendran R; Jain M; Nava VE
Curr Oncol; 2024 Mar; 31(3):1556-1561. PubMed ID: 38534951
[TBL] [Abstract] [Full Text] [Related]
2. Flubendazole suppresses VEGF-induced angiogenesis in HUVECs and exerts antitumor effects in PC-3 cells.
Zhang B; Zhao J; Kang D; Wang Z; Xu L; Zheng R; Liu A
Chem Biol Drug Des; 2024 Mar; 103(3):e14503. PubMed ID: 38480495
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
4. Performance of deep learning models for response evaluation on whole-body bone scans in prostate cancer.
Han S; Oh JS; Seo SY; Lee JJ
Ann Nucl Med; 2023 Dec; 37(12):685-694. PubMed ID: 37819584
[TBL] [Abstract] [Full Text] [Related]
5. Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
Montico F; Lamas CA; Rossetto IMU; Baseggio AM; Cagnon VHA
J Mol Histol; 2023 Aug; 54(4):379-403. PubMed ID: 37335420
[TBL] [Abstract] [Full Text] [Related]
6. Phthalazone tethered 1,2,3-triazole conjugates: In silico molecular docking studies, synthesis, in vitro antiproliferative, and kinase inhibitory activities.
Abdelgawad MA; Bukhari SNA; Musa A; Elmowafy M; Nayl AA; El-Ghorab AH; Sadek Abdel-Bakky M; Omar HA; Hadal Alotaibi N; Hassan HM; Ghoneim MM; Bakr RB
Bioorg Chem; 2023 Apr; 133():106404. PubMed ID: 36812829
[TBL] [Abstract] [Full Text] [Related]
7. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
8. A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo.
Mi YY; Ji Y; Zhang L; Sun CY; Wei BB; Yang DJ; Wan HY; Qi XW; Wu S; Zhu LJ
Cell Death Dis; 2023 Jan; 14(1):67. PubMed ID: 36709328
[TBL] [Abstract] [Full Text] [Related]
9. Heteronuclear Ru(II)-Re(I) complexes as potential photodynamic anticancer agents with anti-metastatic and anti-angiogenic activities.
Ma XR; Lu JJ; Huang B; Lu XY; Li RT; Ye RR
J Inorg Biochem; 2023 Mar; 240():112090. PubMed ID: 36543061
[TBL] [Abstract] [Full Text] [Related]
10. Design, synthesis and computational study of new benzofuran hybrids as dual PI3K/vegfr2 inhibitors targeting cancer.
El-Khouly OA; Henen MA; El-Sayed MA; El-Messery SM
Sci Rep; 2022 Oct; 12(1):17104. PubMed ID: 36224254
[TBL] [Abstract] [Full Text] [Related]
11. Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in cancer Therapy.
Gales L; Forsea L; Mitrea D; Stefanica I; Stanculescu I; Mitrica R; Georgescu M; Trifanescu O; Anghel R; Serbanescu L
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143915
[TBL] [Abstract] [Full Text] [Related]
12. Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
Wang J; Li J; Yin L; Pu T; Wei J; Karthikeyan V; Lin TP; Gao AC; Wu BJ
Oncogene; 2022 Sep; 41(37):4307-4317. PubMed ID: 35986103
[TBL] [Abstract] [Full Text] [Related]
13. Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and vegfr-2 kinases inhibitors.
Ali IH; Abdel-Mohsen HT; Mounier MM; Abo-Elfadl MT; El Kerdawy AM; Ghannam IAY
Bioorg Chem; 2022 Sep; 126():105883. PubMed ID: 35636123
[TBL] [Abstract] [Full Text] [Related]
14. Production and Conjugation of Truncated Recombinant Diphtheria Toxin to vegfr-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line.
Shajari S; Farajollahi MM; Behdani M; Tarighi P
Mol Biotechnol; 2022 Nov; 64(11):1218-1226. PubMed ID: 35478310
[TBL] [Abstract] [Full Text] [Related]
15. Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.
Eke I; Aryankalayil MJ; Bylicky MA; Makinde AY; Liotta L; Calvert V; Petricoin EF; Graves EE; Coleman CN
Sci Rep; 2022 Mar; 12(1):3500. PubMed ID: 35241721
[TBL] [Abstract] [Full Text] [Related]
16. 4-Acetylantroquinonol B Suppresses prostate cancer Growth and Angiogenesis via a VEGF/PI3K/ERK/mTOR-Dependent Signaling Pathway in Subcutaneous Xenograft and In Vivo Angiogenesis Models.
Huang TF; Wang SW; Lai YW; Liu SC; Chen YJ; Hsueh TY; Lin CC; Lin CH; Chung CH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163369
[TBL] [Abstract] [Full Text] [Related]
17. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract] [Full Text] [Related]
18. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as vegfr-2 inhibitors.
Abdallah AE; Mabrouk RR; Al Ward MMS; Eissa SI; Elkaeed EB; Mehany ABM; Abo-Saif MA; El-Feky OA; Alesawy MS; El-Zahabi MA
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):573-591. PubMed ID: 35012403
[TBL] [Abstract] [Full Text] [Related]
19. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA
EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764
[TBL] [Abstract] [Full Text] [Related]
20. Ultrasound Molecular Imaging for the Guidance of Ultrasound-Triggered Release of Liposomal Doxorubicin and Its Treatment Monitoring in an Orthotopic Prostatic Tumor Model in Rat.
Helbert A; von Wronski M; Mestas JL; Tardy I; Bettinger T; Lafon C; Hyvelin JM; Padilla F
Ultrasound Med Biol; 2021 Dec; 47(12):3420-3434. PubMed ID: 34503895
[TBL] [Abstract] [Full Text] [Related]
[Next]
